Core Insights - Cumberland Pharmaceuticals announced new research showing Caldolor (ibuprofen) injection has safety and healthcare resource advantages over ketorolac in both adult and pediatric populations [1][2] - The study indicates that Caldolor is linked to fewer adverse drug reactions (ADRs) and improved healthcare utilization compared to ketorolac [1][3] Study Overview - The research involved a retrospective analysis of over 17 million patient records, focusing on 31,046 adult patients using Caldolor and 124,184 using ketorolac, along with 5,579 pediatric patients in separate claims analysis [2] Key Findings - In adults, Caldolor showed a 45% reduction in renal dysfunction (p<0.001) and a 78% decrease in hematuria rates (p<0.001) compared to ketorolac [3] - Pediatric patients experienced a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals indicating clinical significance [3] Healthcare Resource Utilization - Caldolor demonstrated a positive impact on healthcare resource utilization, leading to decreased emergency room and outpatient visits, as well as shorter hospital stays for both adults and children [4] Company Perspective - The CEO of Cumberland Pharmaceuticals emphasized that these findings highlight Caldolor's potential to enhance patient care by reducing treatment complications and offering potential savings for healthcare systems through decreased hospital readmissions and shorter treatment times [5] Product Information - Caldolor is indicated for managing mild to moderate pain and reducing fever in both adults and pediatric patients, being the first FDA-approved intravenous therapy for fever [6]
New Study Compares Caldolor® (ibuprofen injection) to ketorolac